Gastrin I (human): A High-Purity Regulator for Gastric Acid Secretion Pathway Research

Executive Summary: Gastrin I (human) is an endogenous peptide hormone used as a research-grade CCK2 receptor agonist that directly stimulates gastric acid secretion in vitro (APExBIO, product page). The B5358 kit offers ≥98% purity, validated by HPLC and mass spectrometry, and is soluble in DMSO at concentrations ≥21 mg/mL. Used in combination with advanced human intestinal organoid models, Gastrin I (human) enables mechanistic studies of receptor-mediated signal transduction and proton pump activation (Saito et al. 2025, DOI). It is not recommended for long-term solution storage and should be handled under desiccated, -20°C conditions for stability. Its role in dissecting gastrointestinal pathophysiology and pharmacokinetics is supported by recent organoid and stem cell research (Saito et al. 2025, DOI).

Biological Rationale

Gastrin I (human) is a peptide hormone secreted by G-cells in the gastric antrum. It regulates gastric acid secretion via activation of the CCK2 (cholecystokinin B) receptor on parietal cells. Upon receptor engagement, Gastrin I (human) enhances the stomach's ability to break down proteins and absorb nutrients. The peptide also modulates growth and differentiation of the gastric mucosa. In humans, the gastric acid secretion pathway is critical for oral drug absorption and initial metabolism (Saito et al. 2025, DOI). Dysregulation of this pathway is associated with peptic ulcers, Zollinger-Ellison syndrome, and certain gastrointestinal cancers (APExBIO product page). The ability to study these processes in human-relevant models, such as hiPSC-derived intestinal organoids, has advanced understanding of gastrointestinal physiology and pharmacokinetics.

Mechanism of Action of Gastrin I (human)

Gastrin I (human) binds with high specificity to the CCK2 receptor (also called the gastrin/CCK-B receptor) on gastric parietal cells. This interaction activates G-protein coupled receptor (GPCR) signaling cascades, leading to increased intracellular calcium levels. Downstream, this stimulates the H⁺/K⁺-ATPase proton pump, resulting in enhanced secretion of gastric hydrochloric acid (HCl) into the stomach lumen. The process is tightly regulated and can be studied in vitro using organoids or primary cell cultures (Mechanistic Insights and Benchmarking). Specifically, the molecular sequence of Gastrin I (human) allows for precise receptor engagement, distinguishing its effect from CCK1 (A) receptor ligands. The peptide's action is dose-dependent and typically observed at micromolar concentrations in DMSO-based systems. No significant activity is seen when insoluble in aqueous buffers, underscoring the importance of appropriate solvent selection (APExBIO).

Evidence & Benchmarks

• Human Gastrin I robustly stimulates CCK2 receptor-mediated gastric acid secretion in vitro (Saito et al. 2025, DOI).
• Purity of ≥98% is confirmed for APExBIO B5358 by HPLC and mass spectrometry (APExBIO).
• Solubility in DMSO is documented at concentrations ≥21 mg/mL; insoluble in water and ethanol (APExBIO).
• hiPSC-derived intestinal organoids expressing enterocyte markers and CYP enzymes can serve as human-relevant models for Gastrin I (human) response studies (Saito et al. 2025, DOI).
• Gastrin I (human) is used as a standard agonist in functional benchmarking of CCK2 receptor activity in pharmaceutical and academic research (Advancing Intestinal Organoid).

This article extends 'Unlocking Next-Generation Models for Gastric Secretion' by providing validated purity parameters and addressing workflow constraints in DMSO-based systems, clarifying solvent compatibility not previously detailed. It also updates 'Mechanistic Insights and Benchmarking' by referencing the latest hiPSC-organoid pharmacokinetic results (Saito et al. 2025, DOI).

Applications, Limits & Misconceptions

Gastrin I (human) is widely employed in studies of gastric acid secretion pathway research, particularly as a CCK2 receptor agonist. Key applications include:

• Modeling gastric acid secretion and proton pump activation in vitro.
• Evaluating receptor-mediated signal transduction in gastrointestinal physiology studies.
• Benchmarking CCK2 receptor agonist potency in drug discovery programs.
• Integrating into intestinal organoid systems for translational gastrointestinal disorder research (Transforming Gastric Acid Secretion Research).
• Dissecting pharmacokinetic properties and metabolic enzyme responses in hiPSC-derived models (Saito et al. 2025, DOI).

Common Pitfalls or Misconceptions

• Gastrin I (human) is not active in aqueous or ethanol solutions due to insolubility; DMSO is required for functional studies (APExBIO).
• It does not stimulate CCK1 (A) receptors; selectivity is for CCK2 only.
• Long-term storage of peptide solutions leads to degradation; use immediately after reconstitution.
• In vivo effects may not be replicated in vitro due to microenvironmental differences.
• Species-specific responses may limit translatability from rodent to human systems.

Workflow Integration & Parameters

Researchers should handle Gastrin I (human) as a white lyophilized solid and store it desiccated at -20°C. Reconstitute only in DMSO at ≥21 mg/mL for biological assays. Avoid repeated freeze-thaw cycles. Use freshly prepared solutions for maximal activity. Incorporate into gastric acid secretion models with primary human parietal cells or hiPSC-derived intestinal organoids. Validate functional readouts (e.g., H⁺ secretion, CCK2 activation) within 2–4 hours of peptide addition. The B5358 kit from APExBIO offers batch-level QC data for reproducibility (product page).

Conclusion & Outlook

Gastrin I (human) is a benchmark CCK2 receptor agonist that underpins high-resolution studies of gastric acid secretion and receptor-mediated signal transduction. Its high purity and validated mechanism of action make it suitable for integration with next-generation in vitro models, including hiPSC-derived intestinal organoids. However, careful attention to solvent compatibility and storage is critical for reliable results. Future research will likely expand its use in pharmacokinetic profiling and disease modeling, leveraging organoid technology for greater translational relevance (Saito et al. 2025, DOI).